Wikidata

(Q64679468)

English

A Study of TMC435 in Combination With Pegylated Interferon Alp\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment

clinical trial

In more languages

Statements

short name
PILLAR (English)
0 references
title
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Trial to Investigate the Efficacy, Tolerability, Safety and Pharmacokinetics of TMC435 as Part of a Treatment Regimen Including Peginterferon Alfa-2a and Ribavirin In Treatment-Naive Genotype 1 Hepatitis C-Infected Subjects (English)
0 references
medical condition
hepatitis C
0 references
hepatitis
0 references
hepatitis A
0 references
country
Australia
0 references
Austria
0 references
Belgium
0 references
Canada
0 references
Denmark
0 references
France
0 references
Germany
0 references
New Zealand
0 references
Norway
0 references
Poland
0 references
Spain
0 references
start time
June 2009
0 references
end time
April 2010
0 references
number of participants
386
0 references
minimum age
18 year
0 references
maximum age
70 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q64679468&oldid=2086642647"